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The present report describes the severe evolution of Kawasaki disease in a three-month-old infant. The ailment was
initially atypical in its presentation, with the patient exhibiting only persistent fever in association with a progressive
lethargy and maculopapular rash on the face, trunk and limbs erroneously diagnosed as roseola infantum. On the
10th day of the condition, mainly due to the unexplained persistence of fever, the infant was admitted to a local
hospital. The typical features of KD appeared only on the 14th day of illness with the relapse of the maculopapular
rash in association with non-purulent conjunctivitis; dry, reddish and fissured lips; tongue with reddish and
hypertrophic papillae; erythema and edema of the palms and soles. During the following days, the ailment rapidly
evolved to a catastrophic clinical picture characterized by generalized vasculitis, splenic infarction, pulmonary
thrombosis, giant right and left coronary aneurysms, dilatation of common and internal iliac arteries and
progressive ischemia of the distal third of the feet resulting in necrotic lesions of both halluces. Appropriate therapy
was initiated, but repeated administration of intravenous immunoglobulin G (IVIG) followed by three days of
administration of methylprednisolone did not abate the intense inflammatory activity. The remission of
inflammation and regression of vascular lesions were only achieved during the following five weeks after the
introduction of methotrexate associated with etanercept. The report of this case aims to draw attention to severe
forms of KD that exhibit an unfavorable evolution and can be extremely refractory to the conventional therapy.
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Kawasaki disease (KD) is a vasculitis occurring in infants
and children characterized by prolonged fever; poly-
morphous skin rash; erythema of the oral mucosa, lips
and tongue; erythema, desquamation and swelling of the
palms and soles; bilateral conjunctival injection; and cer-
vical lymphadenopathy. KD is the most common cause
of multisystem vasculitis in childhood; although it can
cause vasculitis in several organs, such as the lungs, liver,
kidneys, intestine, gallbladder and brain, the most* Correspondence: pratesiunb@gmail.com
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distribution, and reproduction in any mediumcommonly damaged are the coronary arteries, frequently
resulting in the formation of aneurysms and stenosis.
Thus, Kawasaki disease is the leading cause of acquired
heart disease in children in developed countries [1].
Despite the numerous theories that have been sug-
gested regarding its etiology, the cause of KD remains
unknown. Treatment with intravenous immunoglobulin
(IVIG) still persists as the mainstay of KD therapy, redu-
cing the rate of coronary aneurysm formation from 25%
to 3-5% [2]. Resistance to IVIG therapy appears to be in-
creasing with reported resistance rates of 20-30% [3].
KD is rare in infants under three months of age. Early
diagnosis and treatment of these infants poses a special
challenge because they are the least likely to present
with signs and symptoms meeting the criteria of persist-
ent fever and at least four of the five other characteristictral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Erythema and induration at the site of previous
vaccination with BCG.
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propriate therapy and may be the reason for the
increased frequency of coronary artery abnormalities
observed in this age group [4]. In this report, we de-
scribe a case of a 3-month-old infant with IVIG and
steroid-resistant KD associated with peripheral gangrene,
splenic infarction, dilated iliac arteries, pulmonary
thrombosis and giant coronary artery aneurysms.
Case report
A three-month-old girl without a previous history of
health problems began to show persisting fever (38°C)
that appeared one day after meningococcal vaccination.
On the 5th day of continuous fever, a maculopapular
rash covering the face, trunk and limbs was observed
and considered to be due to roseola infantum. The rash
subsided after three days, but the infant continued fe-
brile, became progressively lethargic and was admitted
for diagnostic investigation on the 10th day of illness. On
admission, laboratory investigation showed white blood
cell count (WBC) of 25 000/mm3 (68% of neutrophil,
and 7% of band cells), hemoglobin concentration of
6.5 g/dL, platelet count of 237.000/mm, and serum C-
Reactive Protein (CRP) of 19.4 mg/dL (normal value:
≤ 0.5 mg/dL). Chest X-ray imaging was compatible with
right upper lobe pneumonia. In view of the child’s leth-
argy associated with increasing irritability, a lumbar
puncture was performed that yielded 142 WBCs (70%
of neutrophils), 43 mg/dL of glucose and 134 mg/dL
of protein. An intravenous wide-spectrum antibiotic
(ceftriaxone) was initiated.
Typical clinical characteristics of KD only appeared in
this infant on the 14th day of illness with the relapse of
the maculopapular rash in association with bilateral non-
purulent conjunctivitis; dry, reddish and fissured lips;
tongue with reddish and hyperthrophic papillae; and ery-
thema and edema of the palms and soles that quickly
evolved into a deficit of perfusion, with progressive is-
chemia of the distal third of the feet. Despite the reintro-
duction of intravenous wide-spectrum antibiotics
(cefepime and vancomycin) and the administration of
dopamine, a progressive cyanosis of the toes was
observed, followed by hypothermia and blackening of
both halluces. Anticoagulant therapy was started with
enoxaparin. Inflammation was observed at the site of the
BCG vaccination scar (Figure 1) in association with a
marked hyperemia of the anal region. An arterial Dop-
pler ultrasound of the lower limbs disclosed an absence
of blood flow in the distal tibiofibular branches, and
alprostadil IV was started soon after. A computed angio-
tomography showed significant dilatation of both iliac
arteries (Figure 2), foci of rounded opacities in both
lungs suggestive of pulmonary thrombosis, and a hypo-
dense area in the splenic parenchyma suggestive ofinfarction (Figure 3). At this time a first echocardiog-
raphy disclosed normal coronary arteries and mild mitral
regurgitation. Blood and CSF cultures yielded negative
results, but inflammatory markers remained extremely
high (erythrocyte sedimentation rate (ESR) 120 mm/h,
CRP 34 mg/dL and alpha-1-acid glycoprotein 160 mg/
dL). Serologic tests for cytomegalovirus, parvovirus, ru-
bella, and Epstein Barr virus were negative. Soon after
the diagnosis was established, a 2 g/kg/dose of intraven-
ous immunoglobulin (IVIG) was administered in associ-
ation with 80 mg/kg/day of acetylsalicylic acid (ASA) in
divided doses. The administration of enoxaparin was
suspended two days after the IVIG administration be-
cause the ischemic injury of the halluces did not show
progression.
On the 17th day of illness, the high fever still persisted
in association with significant signs of inflammatory ac-
tivity. Three days after the administration of this first
dose of IVIG, the high inflammatory activity had not
subsided (CRP 29.2 mg/dL, alpha-1-acid glycoprotein
143 mg/dl), and a repeated echocardiogram showed
moderate pericardial effusion associated with mild mitral
regurgitation and significant dilatation (5.2 mm in diam-
eter) of both coronary arteries. The dosage of ASA was
decreased to 5 mg/kg/day, as a platelet anti-adhesive
agent due to the presence of coronary artery lesions. A
single daily dose of 30 mg/kg/day of methylprednisolone
IV was started and maintained for three days, followed
by prednisolone at a dosage of 2 mg/kg/day, to reduce
the inflammatory activity.
In spite of these therapeutic measures the child per-
sisted with fever, inflammatory activity (CRP 8.20 mg /dL)
and an increased platelet count (905.000/mm³). Seven
days after the first administration, a second 2 g/kg dose
of IVIG was given followed by a rapid decline of the
fever and improvement of the anal mucositis, the in-
flammation of the BCG scar and the degree of vasculitis
in her feet. A new echocardiogram that was performed
eight days after the second IVIG dose showed increase
in the previously observed dilatation of the left coronary
Figure 2 Whole-body angio-tomography showing the aorta with a normal diameter and significant dilatation of both iliac arteries (see
detail in the upper right side of the image).
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lone IV at a dosage of 30 mg/kg/day was reinitiated and
maintained for three days, followed by prednisolone at
2 mg/kg/day to reduce the inflammatory activity.
The infant was finally discharged for follow-up at
the walk-in Clinics of Pediatric Rheumatology and
Pediatric Cardiology, with the prescription of 5 mg/kg/
day of ASA, 2 mg/kg/day of prednisolone and
3.75 mg/kg/day of clopidogrel. Despite her progressive
clinical improvement and her normal platelet count
(434,000 mm3), 15 days after discharge, she still showed
increased inflammatory activity (CRP 10.53 mg/dL,
alpha-1-acid glycoprotein 183 mg/dL), total cholesterol
(232 mg/dL) and LDL (157 mg/dL). Her echocardiogram
showed aneurysms of 5 mm and 7 mm respectively on
the right and left coronary arteries, associated with a
dilation of 3.5 mm in the anterior descending branch of
the left coronary artery. Methotrexate at 0.5 mg/kg /week
P.O. and etanercept at 0.8 mg/kg/week administeredsubcutaneously were added to the drugs already in
use.
Five weeks after discharge, the infant was considered
to be in clinical remission with inflammatory activity
tests, echocardiography, LDL and total cholesterol yield-
ing normal results. On this occasion, a repeated echocar-
diogram disclosed a significant reduction in the
diameter of the aneurysms to 4 mm and 5.5 mm re-
spectively for the right and left coronary arteries, and to
3.2 mm for the anterior descending artery. The child’s
condition improved over the next eight months without
any clinical or laboratory evidence of inflammatory ac-
tivity, showing a further regression of her coronary ar-
tery abnormalities with the diameters decreasing to
2.4 mm and 3.6 mm respectively for the right and left
coronary arteries and to 2.3 mm for the anterior des-
cending artery.
The sequential stages of this infant’ KD evolution are
summarized in Table 1.
Figure 3 Whole-body angio-tomography showing area of hypodensity in the splenic parenchyma suggestive of splenic infarction.
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This case highlights both the difficulty of reaching a de-
finitive diagnosis in some cases of KD and the severity
of this disorder in very young infants. Although KD has
been described in different ethnic and racial groups and
in all pediatric age groups, its highest incidence is in
children under 5 years. Its incidence below six months is
relatively rare and even rarer under three months of age.
A review of a Japanese database of 105,755 cases
reported over a 25-year period yielded only six cases
aged 30 days or younger and 1768 cases (1.67%) aged
90 days or younger [5]. Children three months old or
younger are more prone to cardiac complications and
are frequently affected by an incomplete form of the dis-
ease that generally hampers and delays the diagnosis [6].
Another unusual manifestation of this case was that
aseptic meningitis was detected as one of the initial
manifestations of the disease. Aseptic meningitis has
been generally described as an event that occurs during
the acute phase of KD [7,8]. Other neurological manifes-
tations such as intense irritability, seizures, ataxia, leth-
argy or coma, subdural collection, hemiplegia, facial
palsy and sensorineural hearing loss can also be detected
in approximately 1.3 to 3.7% of cases [9,10]. CNS lesions
should always be considered, especially in severe cases
accompanied by intense and prolonged inflammatory ac-
tivity [11].
Aside from the prolonged fever, many of the diagnostic
criteria required to establish a definitive diagnosis of KD
appeared in this infant only after the 14th day of illness.This led to a delayed diagnosis and delayed treatment
with IVIG that should have been administered within
the first 10 days of illness. The lack of appropriate ther-
apy with IVIG within the first 10 days in association
with prolonged high fever, high inflammatory activity,
anemia and hypoalbuminuria in younger infants are all
considered predisposing factors for developing coronary
aneurysms [1].
This young infant’s disease progression was unusually
severe, even for the severe course sometimes seen in
infants under six month with KD, and certainly more se-
vere than older children with KD. This age group gener-
ally exhibits an increased frequency of coronary damage
[12]. The exceptional severity of this case was mainly
due to the involvement of various organs (lung, spleen,
heart) and several arteries (coronary arteries, anterior
descending branch of the left coronary artery and both
iliac arteries). The abnormalities of the coronary arteries
were exceptionally severe, with their size rapidly increas-
ing to a diameter five times larger than that expected for
the patient’s age. In addition to the unfavorable and se-
vere course of the disease, this infant failed to appropri-
ately respond to repeated administrations of 2 g/kg/day
of IVIG, and followed by two three-day courses of
30 mg/kg/day methylpredisolone IV and subsequent
maintenance dose of 2 mg/kg/day of prednisone. Despite
this therapeutic approach, the progression of the inflam-
matory activity and aneurysms continued unabated.
Approximately15% of patients with KD fail to respond
to the first dose of IVIG, and this group generally
Table 1 Major landmarks in the evolution of Kawasaki disease in this three-year old infant
Days of
evolution
Clinical signs Laboratory data Therapy
Day 1 to 9th Fever; maculopapular rash; lethargy
10th day Hospital admission; persisting fever High CRP; chest X-ray: pneumonia;
CSF: aseptic meningitis
Wide spectrum antibiotic (ceftriaxone)
14th day KD characteristic clinical signs,
persisting fever, cyanosis of toes
and blackening of halluces,
reactivation of BCG scar
Doppler ultrasound: absence of
blood flow in distal tibiofibular
branches. Computed angio-
tomography: dilatation of both iliac
arteries; pulmonary thrombosis;
splenic infarction. 1st Echocardiogram:
normal coronary arteries. High levels
of inflammatory markers.
Reintroduction of wide- spectrum
antibiotics (cefepime & vancomycin);
anticoagulant therapy: enoxaparin;
alprostadil; 1st administration of IVIG
& ASA (80 mg/kg/day),
17th day Persisting fever Inflammatory markers still high; 2nd
echocardiogram: significant dilatation
of coronary arteries
ASA decreased to (80 mg/kg/day);
Started three daily doses of 30
mg/kg/day of methylprednisolone
IV followed by 2 mg/kg/day of
prednisolone;
21th day Persisting fever Inflammatory markers still high; 2nd administration of IVIG
29th day Fever decline; improvement of feet
vasculitis and BCG scar inflammation
3rd echocardiogram: increasing dilatation
of left coronary artery; pericardial effusion.
Restarted methylprednisolone IV
(30 mg/kg/day), followed by 2
mg/kg/day of prednisolone.
35th day Hospital discharge Persisting abnormal levels of
inflammatory markers;
Discharge prescription: ASA 5
mg/kg/day and clopidogrel 3.75
mg/kg/day
51st day Persisting abnormal levels of inflammatory
markers; 4th echocardiogram: aneurysms
on right and left coronary arteries and
dilatation of the descending branch of
left coronary artery.
Methotrexate 0.5 mg/kg/week
P.O. and etanercept 0.8 mg/kg/week
added to drugs already in use
85th day Considered in clinical remission Normal results of inflammatory activity
tests; 5th echocardiogram : reduction of
aneurysm and anterior descending
artery dilatation
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In those patients in whom a second dose of IVIG did
not result in a satisfactory clinical response, the adminis-
tration of corticosteroids may eventually reduce the de-
gree of inflammatory activity even though it usually does
not slow the progression of aneurysms [1,16]. As far as
we know, there is no established protocol for those cases
in which the above-mentioned measures did not achieve
the desired results. Several different therapeutic
approaches have been adopted, mostly based on case
reports or non-randomized or uncontrolled trials, with
apparently favorable outcomes. Immunosuppressive
agents such as cyclophosphamide or cyclosporine in as-
sociation with prednisone or methylprednisolone have
been used and resulted in a decrease in fever although
they failed to show substantial effects on the progression
of coronary abnormalities [17].
Recently, in view of the multiple lines of scientific evi-
dence supporting the prominent role of tumor necrosis
factor-α (TNF-α) in mediating inflammation in acute
and refractory KD, a new class of biological agents hasemerged for the treatment of patients with refractory
KD. Monoclonal antibodies to TNF (infliximab) [18] and
a soluble form of TNF receptor fusion protein that
antagonizes the effects of endogenous TNF (etanercept)
showed satisfactory results in several cases of refractory
KD leading to a decline in fever and inflammatory activ-
ity and to a regression of coronary abnormalities [19,20].
A low dose of methotrexate has also been used to treat
patients with resistant KD and has shown promising
results with a rapid decrease in fever, improvement in
clinical symptoms and normalization of acute phase
reactants [20-22].
The treatment in the subacute phase and in convales-
cent patients with coronary aneurysms is aimed at pre-
venting vessel thrombosis. A low dose of aspirin (3 to
5 mg/kg/day) is the main treatment for children with
small and medium-sized aneurysms and may be contin-
ued for a prolonged time. Other agents may also be used
in association with aspirin such as antiplatelet agents
(clopidogrel, ticlopidine, dipyridamole) and show an
increased effectiveness in blocking platelet aggregation.
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agents such as low molecular weight heparin that was
used in this case, and warfarin and monoclonal anti-
bodies against the platelet receptor IIb / IIIa in the man-
agement of children with giant aneurysms [1].
Conclusion
In conclusion, the prognosis of KD in infants can be par-
ticularly severe, and clinicians should be suspicious of
atypical KD in younger infants with persistent fever even
if all the criteria for KD are not met. In the present case,
despite the adverse clinical progression and imminent risk
of infant death, a successful response was finally obtained
through combined treatment with methotrexate and eta-
nercept that resulted in a satisfactory remission of the
patient’s clinical symptoms within five weeks along with a
normalization of laboratory results, associated with a
gradual decrease in the diameters of the aneurysms.
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